The world's largest animal health company is moving forward with its pledge to become a little less large. In its second deal in two weeks, Zoetis will sell a production site and some of its products in India to Zydus Cadila as part of its pledge to close 10 plants and cut about 2,500 employees as it strives to improve margins.
Activist investor and one-time Valeant deal partner Bill Ackman has been pretty gung-ho about the Canadian pharma as an investment prospect, even as controversy has battered its shares. Now, though, he's paring down his hedge fund's stake.
Vivus has never had a marketing partner for flailing obesity therapy Qsymia--and now, it's about to be one short for erectile dysfunction therapy Stendra, too. Last week, Endo's Auxilium Pharmaceuticals announced in a regulatory filing that it would be terminating its licensing pact--covering the U.S. and Canada--with the California drugmaker, with an end date of June 30.
2016 is the year that GlaxoSmithKline is supposed to start to show the results of CEO Andrew Witty's turnaround efforts. Well 2016 is here and Witty is expected to show up at the JP Morgan Healthcare Conference next week with plans he hopes will convince investors that his efforts to remake the British pharma giant have not been in vain.
The FDA is continuing its efforts to raise the standards of India's pharma industry, closing out the year with a warning to Cadila Healthcare, the company acknowledged in a report to the Bombay Stock Exchange. The citation follows warnings last year for a host of Indian drugmakers including Sun Pharmaceutical, Dr. Reddy's Laboratories and Mylan's sterile injectable operations in India.
Roche is burying the hatchet with India's Glenmark in a patent war over its cancer drug Tarceva, settling outstanding litigation with the company even as it wages a battle with another Indian generics maker over a patent for the med.
It's taken a months-long pursuit, but Shire is finally reportedly on the verge of nabbing target Baxalta.
Last week, Valeant confirmed that CEO J. Michael Pearson had been hospitalized with a severe case of pneumonia--and now, he's taking a medical leave of absence.
Drug prices were already a sore subject, but the pain grew this fall, when the now-former CEO of Turing Pharmaceuticals Martin Shkreli unapologetically jacked up the price of a 62-year-old drug by 5,000%-plus--to $750 per pill from $13.50. Unfortunately, that pain is going to continue into 2016.
If you think 2015 was a big year in pharma M&A, just wait. That train won't be slowing down any time soon, industry watchers say. On the contrary, they're expecting even more deal activity next year.
Martin Shkreli has already been ousted as CEO of KaloBios. And now, Nasdaq plans to delist the company, citing Shkreli's recent arrest on fraud and looting charges as one reason for the move.
Winter days are short and dark. December is winding down. If you're not already on a holiday break, you likely will be soon. So, it's a good time to take a minute to think about what's ahead in the new year.
There's not going to be a beyond-the-pill revolution in 2016. Frankly, pharma doesn't yet have the technology to move beyond pushing products to delivering outcomes. But drugmakers are teaming up with major technology players in deals that marry Big Data record-sifting with cutting-edge patient-monitoring gadgetry, and that's the kind of infrastructure necessary for big moves beyond the pill.
With one biosim already on the U.S. market, and more poised for a 2016 liftoff, next year will give drugmakers and payers a taste of the biosim contest to come.
A bumper crop of FDA approvals in 2015 means an equal number of launches to keep an eye on in 2016. Last year, FiercePharmaMarketing brought you a list of 8 markets to watch--including some bracing for the next-gen entrants that arrived in 2015. One year later, those newcomers are shaking things up as expected.
Good news for Gilead Sciences and Bristol-Myers Squibb: Australia's federal government wants to eliminate hepatitis C in the country. And it plans to shell out $1 billion on the drugmakers' meds to do that.
The wait for outcomes data on Amgen's PCSK9 drug Repatha just got shorter. As CardioBrief reports, top-line results of a study called Fourier will be available in the second half of 2016.
Germany's Boehringer Ingelheim has been swapping out operations and changing up top management as it scrambles to recover from patent losses that have flattened its revenues. After doing deals to bolster its top line, it will now spend some money on manufacturing in hopes of riding the biopharma boom to greater heights, adding about 400 jobs in the process.
A new group of activist doctors has joined the drug pricing protests. This time, it's neuromuscular specialists, and they're targeting a forthcoming drug, Firdapse, that's likely to turn treatment of a rare disease from a no-cost endeavor to an expensive affair.
Just in time for the holidays, Celgene settled the score with Natco Pharma over patents for its cancer blockbuster Revlimid. The company is allowing the Indian generics maker to start selling copycat versions of its best-selling drug before Revlimid goes completely off patent in 2027, but with a few strings attached.